Stocks · News reference
Trading Halt: Halted at 6:57:27 a.m. ET - Trading Halt: Halt News Pending
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.
Redhill Biopharma Stock Doubles In One Session — Here's Why
RedHill Biopharma divests Talicia to Apotex, boosting liquidity and funding its commercial growth strategy and RHB-102 development.
Redhill Biopharma shares are trading higher after the company announced the divestment of its Talicia business to a subsidiary of Apotex Health.